Description
release form
Capsules
packaging 20 pcs
Pharmacological action
Pharmacodynamics
Anvifen is a nootropic drug that facilitates GABA-mediated transmission of nerve impulses to the central nervous system (direct effect on GABAergic receptors). A tranquilizing effect is combined with an activating effect. It also has antiplatelet, antioxidant and some anticonvulsant effects.
Improves the functional state of the brain by normalizing its metabolism and effect on cerebral blood flow (increases volumetric and linear velocity, reduces vascular resistance, improves microcirculation, and has an antiplatelet effect). It lengthens the latent period and shortens the duration and severity of nystagmus.
Does not affect choline and adrenoreceptors. Reduces vasovegetative symptoms (including headache, feeling of heaviness in the head, sleep disturbance, irritability, emotional lability). With a course admission, it increases physical and mental performance (attention, memory, speed and accuracy of sensory-motor reactions).
Reduces the manifestations of asthenia (improves well-being, increases interest and initiative – the motivation of activity) without sedation or arousal.
Helps reduce feelings of anxiety, tension and anxiety, normalizes sleep.
In elderly people, CNS depression does not cause, muscle-relaxing aftereffect is most often absent.
Pharmacokinetics
Absorption and distribution
Absorption is high, it penetrates well into all body tissues and through the BBB (about 0.1% of the administered dose penetrates into the brain tissue, and to a much greater extent in young and elderly people). Evenly distributed in the liver and kidneys.
Metabolism and excretion
Metabolized in the liver – 80 95%, metabolites are pharmacologically inactive. Does not cumulate. After 3 hours, it begins to be excreted by the kidneys, while the concentration in the brain tissue does not decrease and is detected for another 6 hours. About 5% is excreted by the kidneys unchanged, partially with bile.
Contraindications
Hypersensitivity, pregnancy, breastfeeding, children under 3 years of age.
Caution: with erosive ulceration of the gastrointestinal tract, liver failure.
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation (breastfeeding).
Composition
Active ingredient: aminophenylbutyric acid hydrochloride – 50 mg
Excipients: hyprolose – 1.3 mg silicon colloidal dioxide – 3.2 mg lactose – 1/84 mg – 1.4 mg
Hard gelatin capsule: for a dosage of 50 mg – water, gelatin, dye azorubine (E122), dye blue diamond (E133), dye quinoline yellow (E104), titanium dioxide (E171)
Side effects
Drowsiness, nausea. Increased irritability, agitation, anxiety, dizziness, headache (at the first receptions), allergic reactions.
Drug Interaction
Extends and enhances the action of sleeping pills, narcotic analgesics, neuroleptics, antiparkinsonian and antiepileptic drugs.
Overdose
Symptoms: severe drowsiness, nausea, vomiting, fatty liver (intake of more than 7 g), eosinophilia, decreased blood pressure, impaired renal function.
Treatment: gastric lavage, the appointment of activated charcoal and symptomatic therapy.
Storage conditions
The drug should be stored in a dry, dark place, inaccessible to children at a temperature not exceeding 25 ° C.
Expiration
3 Year
Deystvuyuschee substances
Amynofenylmaslyanaya acid
Dosage form
dosage form
capsules
Pharmproject, Russia
